Leadership

OvaScience is a global life sciences company dedicated to improving fertility for women around the world.

 

Leadership Team

MICHELLE DIPP, M.D., PH.D.
Executive Chair and Co-Founder

Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp has co-founded Longwood portfolio companies OvaScience (NASDAQ: OVAS) where she serves as Chairman of the Board and previously served as CEO, Axial Biotherapeutics, where she serves as Chairman of the Board, Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and Flex Pharma (NASDAQ: FLKS). Previously, Dr. Dipp was the Senior Vice President and Head of GlaxoSmithKline’s (NYSE: GSK) Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK’s CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GSK). Before joining Sirtris as a co-founder, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, and the Boston Symphony Orchestra Board of Overseers. In 2015, Dr. Dipp was elected to join the World Economic Forum’s Young Global Leaders and was named to Fortune magazine’s 40 Under 40 list. Dr. Dipp is the women’s health contributor for Arianna Huffington’s Thrive Global.

Dr. Dipp holds a BM, BCh (MD equivalent) from University of Oxford Medical School and a DPhil (PhD equivalent) in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford.

CHRISTOPHE COUTURIER, M.B.A.
Chief Financial Officer

Mr. Couturier brings 30 years of experience with a proven record in management, finance and strategic planning across multiple geographies to OvaScience. Most recently, he served as Senior Vice President and General Manager at Merck KGaA (Darmstadt, Germany), where he led the Merck KGaA/Pfizer Global Immuno-Oncology Alliance. Previously, he worked in a series of roles at MilliporeSigma, including serving as Senior Vice President of the Merck KGaA/Sigma-Aldrich Integration Program, Vice President of Corporate Financial Planning and Analysis and Vice President of Finance Operations for the company’s Bioprocess and BioScience divisions. Prior to joining Merck KGaA in 2004, Mr. Couturier worked as an Associate Partner at IBM Business Consulting Services, as a Finance Director at Lloyds Pharmacy and as a Head of Finance for Novartis, with positions in Hungary, Norway, Turkey and Switzerland.

Mr. Couturier holds an M.B.A. from ESSEC Business School in France.

JAMES D. LUTERMAN, PH.D.
EVP, Research and Development

Dr. Luterman has been with OvaScience since January 2014 and most recently served as Senior Vice President, Research & Development. He brings over 20 years of industry experience to the Company. Prior to OvaScience, Dr. Luterman was an Early Development Team Leader at Shire Human Genetic Therapies, where he led the matrix management of Development Candidates from nomination through IND. Prior to Shire, he was a Program Leader at CombinationRx where he guided program strategy for the company’s flagship product and lead the development team through multiple clinical trials. Earlier in his career he worked at Biogen and Decision Resources Group, where he developed commercial analysis and recommendations for early stage clinical development programs.

Dr. Luterman holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine in New York.